Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard S&P 500 ETF (VOO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Vanguard S&P 500 ETFTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Vanguard S&P 500 ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard S&P 500 ETF trades at $710.23, while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). Which is the better fit depends on your goals.

VOOVRTX
Sector
Broad Market / FactorHealth
52-Week High
$710.71$529.65
52-Week Low
$580.93$376.62
Market Cap
$134.25B
Enterprise Value
$128.37B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard S&P 500 ETF

VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.

Read more on VOO

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX